New study from the Netherlands, below [1].
One would expect bone issues with ADT, since near-zero testosterone equates to near-zero estradiol. When estradiol goes below 12 pg/mL (my limit, based on old non-PCa studies), bone loss can be rapid.
But this study looked at men who were about to start ADT:
"there is a high prevalence of vertebral fractures {VF} in a third of the men with PCa at the time of ADT initiation"
What isn't mentioned is testosterone [T] or estradiol [E2]. Men lose 1-2% of T each year, starting in their early 30s. Men with lower T appear to have a greater risk of PCa. It's not unusual to find T at diagnosis to be close to 350 ng/dL, the cut-off for hypogonadism. Some men fall below 250 ng/dL and are effectively on ADT-Lite.
"In 115 men at ADT initiation, aged 73.3 ... years, osteoporosis was diagnosed in 4.3 %
... and osteopenia in 35.7 %.
... The mean 10-year fracture risk of major osteoporotic fracture was 4.4 % and of hip fracture 1.7 %, respectively.
At least one VF was present in 32.2 %
... and 33.9 % of men had osteoporosis and/or a VF assessed on spinal X-rays.
... In 10.4 % at least one new fracture-risk-associated metabolic bone disorder was diagnosed with laboratory testing."
-Patrick
[1] pubmed.ncbi.nlm.nih.gov/365...
High prevalence of vertebral fractures at initiation of androgen deprivation therapy for prostate cancer
Marsha M van Oostwaard 1 2, Joop P van den Bergh 1 2, Yes van de Wouw 1, Maryska Janssen-Heijnen 3 4, Marc de Jong 5, Caroline E Wyers 1
Affiliations
1 Department of Internal Medicine, VieCuri Medical Centre, P.O. Box 1926, 5900 BX Venlo, the Netherlands.
2 Department of Internal Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre+ (Maastricht UMC+), P.O. Box 616, 6200 MD Maastricht, the Netherlands.
3 Department of Clinical Epidemiology, VieCuri Medical Center, Venlo, the Netherlands.
4 Department of Epidemiology, GROW School for Oncology and Reproduction, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, the Netherlands.
5 Department of Urology, VieCuri Medical Centre, P.O. Box 1926, 5900 BX Venlo, the Netherlands.
PMID: 36591574 PMCID: PMC9798166 DOI: 10.1016/j.jbo.2022.100465
Abstract
Purpose: Treatment of Prostate Cancer (PCa) with Androgen Deprivation Therapy (ADT) involves long-term consequences including bone loss and fractures. Our aim was to evaluate the calculated fracture risk and the prevalence of osteoporosis, vertebral fractures (VF) and sarcopenia in men with PCa at initiation of ADT, as ADT will increase fracture risk from that moment onward.
Methods: In this cross-sectional real-world study in men at ADT initiation, fracture risk factors including comorbidities, medication, and 10-year fracture risk (FRAX®) were assessed. Laboratory tests, dual-energy X-ray absorptiometry, and spinal X-rays were performed. Sarcopenia was defined according to EWGSOP2.
Results: In 115 men at ADT initiation, aged 73.3 (±7.6) years, osteoporosis was diagnosed in 4.3 % and osteopenia in 35.7 %. The mean 10-year fracture risk of major osteoporotic fracture was 4.4 % and of hip fracture 1.7 %, respectively. At least one VF was present in 32.2 % and 33.9 % of men had osteoporosis and/or a VF assessed on spinal X-rays. In 10.4 % at least one new fracture-risk-associated metabolic bone disorder was diagnosed with laboratory testing. Sarcopenia was diagnosed in only one patient.
Conclusions: Although the prevalence of osteoporosis, sarcopenia and 10-years fracture risk is low, there is a high prevalence of vertebral fractures in a third of the men with PCa at the time of ADT initiation. Besides a BMD measurement and fracture risk calculation using FRAX, a systematic vertebral fracture assessment should be considered in all men with PCa at initiation of ADT to provide a reliable baseline classification of VFs to improve identification of true incident VFs during ADT.